Click Holdings Limited (NASDAQ:CLIK) Sees Large Increase in Short Interest

Click Holdings Limited (NASDAQ:CLIK) saw a significant increase in short interest in July. As of July 31st, there was short interest totaling 19,660 shares, an increase of 913.9% from the July 15th total of 1,939 shares. Based on an average daily trading volume, of 577,994 shares, the short-interest ratio is currently 0.0 days. Approximately 1.7% of the company’s stock are sold short.

Click Stock Down 1.4%

Shares of NASDAQ:CLIK traded down $0.02 during trading on Tuesday, hitting $1.44. 16,248 shares of the company were exchanged, compared to its average volume of 364,692. The firm’s 50 day moving average price is $1.53 and its 200-day moving average price is $2.38. Click has a 12-month low of $1.32 and a 12-month high of $14.40.

Click (NASDAQ:CLIK) last posted its earnings results on Monday, May 11th. The company reported $0.10 EPS for the quarter. The company had revenue of $3.79 million during the quarter.

Analyst Ratings Changes

A number of analysts have issued reports on CLIK shares. Wall Street Zen raised Click to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reiterated a “sell (d)” rating on shares of Click in a report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Hedge Funds Weigh In On Click

An institutional investor recently bought a new stake in Click stock. Renaissance Technologies LLC bought a new position in shares of Click Holdings Limited (NASDAQ:CLIK) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click as of its most recent filing with the Securities and Exchange Commission (SEC).

Click Company Profile

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.